Mangrove Partners’s Ocular Therapeutix OCUL Stock Holding History

Mangrove Partners’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-21,416	Closed	-$186K	–	185
2024 Q3	$186K	Buy	+21,416	New	+$177K	0.02%	140

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Mangrove Partners's OCUL Position: Q4 2024 in Review

Mangrove Partners sold out of Ocular Therapeutix (OCUL) in Q4 2024, closing a stake of 21,416 shares — an estimated $186K sold.

Mangrove Partners first reported a position in OCUL in Q3 2024 and held it in 1 quarter. The position peaked at $186K in Q3 2024. 179 funds tracked by Wall St. Rank hold OCUL as of Q4 2024.

Mangrove Partners reported no remaining Ocular Therapeutix position as of Q4 2024 after selling out during the quarter.
Mangrove Partners sold 21,416 Ocular Therapeutix shares in Q4 2024, an estimated $186K.
Mangrove Partners first reported a position in Ocular Therapeutix in Q3 2024 and held it in 1 quarter.
Mangrove Partners's Ocular Therapeutix position peaked at $186K in Q3 2024.
179 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2024.

Based on Mangrove Partners's 13F filing for Q4 2024, filed 14 Feb 2025.